Carla Debernardi

Mrs. Carla Debernardi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2017 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
DFDaniela Furlan
Daniela Furlan
DTDavide Trapani
Davide Trapani
EBEnrico Berrino
Enrico Berrino
CDCarla Debernardi
Carla Debernardi
MPMara Panero
Mara Panero
TVTiziana Venesio
Tiziana Venesio
A compromised base excision repair (BER) promotes carcinogenesis by accumulating oxidative DNA-damaged products as observed in MUTYH-associated polyposis, a hereditary colorectal cancer syndrome marked by adenomas and cancers with an accumulation of 8-oxoguanine. Remarkably, DNA global demethylation has been shown to be mediated by BER, suggesting a relevant interplay with early colorectal tumourigenesis. To check this hypothesis, we investigated a cohort of 49 adenomas and 10 carcinomas, derived from 17 MUTYH-associated polyposis patients; as adenoma controls, we used a set of 36 familial adenomatous polyposis and 24 sporadic polyps. Samples were analysed for their mutational and epigenetic status, measured as global LINE-1 (long interspersed nuclear element) and gene-specific LINE-1 MET methylation by mass spectrometry and pyrosequencing. MUTYH-associated polyposis adenomas were strikingly more hypomethylated than familial adenomatous and sporadic polyps for both DNA demethylation markers (P=0.032 and P=0.007 for LINE-1; P=0.004 and P<0.0001 for LINE-1 MET, respectively) with levels comparable to those of the carcinomas derived from the same patients. They also had mutations due mainly to KRAS/NRAS p.G12C, which was absent in the controls (P<0.0001 for both sets). Our results show that DNA demethylation, together with specific KRAS/NRAS mutations, drives the early steps of oxidative damage colorectal tumourigenesis.

13 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MKMalvina Koni
Malvina Koni
Isabella CastellanoIsabella Castellano
Isabella Castellano
EVEmilio Venturelli
Emilio Venturelli
ASAlessandro Sarcinella
Alessandro Sarcinella
TLTatiana Lopatina
Tatiana Lopatina
MBMaria felice Brizzi
Maria felice Brizzi
Tumour molecular annotation is mandatory for biomarker discovery and personalised approaches, particularly in triple-negative breast cancer (TNBC) lacking effective treatment options. In this study, the interleukin-3 receptor α (IL-3Rα) was investigated as a prognostic biomarker and therapeutic target in TNBC. IL-3Rα expression and patients’ clinical and pathological features were retrospectively analysed in 421 TNBC patients. IL-3Rα was expressed in 69% human TNBC samples, and its expression was associated with nodal metastases (p = 0.026) and poor overall survival (hazard ratio = 1.50; 95% CI = 1.01–2.2; p = 0.04). The bioinformatics analysis on the Breast Invasive Carcinoma dataset of The Cancer Genome Atlas (TCGA) proved that IL-3Rα was highly expressed in TNBC compared with luminal breast cancers (p = 0.017, padj = 0.026). Functional studies demonstrated that IL-3Rα activation induced epithelial-to-endothelial and epithelial-to-mesenchymal transition, promoted large blood lacunae and lung metastasis formation, and increased programmed-cell death ligand-1 (PD-L1) in primary tumours and metastases. Based on the TCGA data, IL-3Rα, PD-L1, and EMT coding genes were proposed to discriminate against TNBC aggressiveness (AUC = 0.86 95% CI = 0.82–0.89). Overall, this study identified IL-3Rα as an additional novel biomarker of TNBC aggressiveness and provided the rationale to further investigate its relevance as a therapeutic target.

16 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
EBEnrico Berrino
Enrico Berrino
UMUmberto Miglio
Umberto Miglio
Sara Erika BellomoSara Erika Bellomo
Sara Erika Bellomo
CDCarla Debernardi
Carla Debernardi
ABAlberto Bragoni
Alberto Bragoni
Anna SapinoAnna Sapino
Anna Sapino
Background: Long-Interspersed Nuclear Element (L1) retrotransposons are silenced in healthy tissues but unrepressed in cancer. Even if L1 reactivation has been associated with reduced overall survival in breast cancer (BC) patients, a comprehensive correlation with clinicopathological features is still missing. Methods: Using quantitative, reverse-transcription PCR, we assessed L1 mRNA expression in 12 BC cells, 210 BC patients and in 47 normal mammary tissues. L1 expression was then correlated with molecular and clinicopathological data. Results: We identified a tumor-exclusive expression of L1s, absent in normal mammary cells and tissues. A positive correlation between L1 expression and tumor dedifferentiation, lymph-node involvement and increased immune infiltration was detected. Molecular subtyping highlighted an enrichment of L1s in basal-like cells and cancers. By exploring disease-free survival, we identified L1 overexpression as an independent biomarker for patients with a high risk of recurrence in hormone-receptor-negative BCs. Conclusions: Overall, L1 reactivation identified BCs with aggressive features and patients with a worse clinical fate.

26 September 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
CDCarla Debernardi
Carla Debernardi
ASAngelo Savoca
Angelo Savoca
AGAlessandro De Gregorio
Alessandro De Gregorio
ECElisabetta Casalone
Elisabetta Casalone
MRMiriam Rosselli
Miriam Rosselli
GMGiuseppe Matullo
Giuseppe Matullo
Background/Objectives: The identification of coronary artery disease (CAD) high-risk individuals is a major clinical need for timely diagnosis and intervention. Many different polygenic scores (PGSs) for CAD risk are available today to estimate the genetic risk. It is necessary to carefully choose the score to use, in particular for studies on populations, which are not adequately represented in the large datasets of European biobanks, such as the Italian one. This work aimed to analyze which PGS had the best performance within the Italian population. Methods: We used two Italian independent cohorts: the EPICOR case–control study (576 individuals) and the Atherosclerosis, Thrombosis, and Vascular Biology (ATVB) Italian study (3359 individuals). We evaluated 266 PGS for cardiovascular disease risk from the PGS Catalog, selecting 51 for CAD. Results: Distributions between patients and controls were significantly different for 49 scores (p-value < 0.01). Only five PGS have been trained and tested for the European population specifically. PGS003727 demonstrated to be the most accurate when evaluated independently (EPICOR AUC = 0.68; ATVB AUC = 0.80). Taking into account the conventional CAD risk factors further enhanced the performance of the model, particularly in the ATVB study (p-value = 0.0003). Conclusions: European CAD PGS could have different risk estimates in peculiar populations, such as the Italian one, as well as in various geographical macro areas. Therefore, further evaluation is recommended for clinical applicability.

30 December 2025 in International Journal of Cancer
Verified
Journal Article
Open access
KHKhadija Sana Hafeez
Khadija Sana Hafeez
CDCarla Debernardi
Carla Debernardi
AAAlessandra Allione
Alessandra Allione
EHElton Jalis Herman
Elton Jalis Herman
SGSimonetta Guarrera
Simonetta Guarrera
GMGiuseppe Matullo
Giuseppe Matullo
Pleural mesothelioma (PM) is a lethal cancer primarily caused by asbestos exposure. Not all exposed individuals develop PM, suggesting the involvement of additional factors. This underscores the need for robust predictive models integrating biomarkers from multi‐omic domains to improve risk stratification and early detection. We developed and evaluated polygenic risk scores (PRS) and methylation risk scores (MRS) using a retrospective case–control study (749 participants: 387 PM cases, 362 controls) and a nested case–control European Prospective Investigation into Cancer and Nutrition (EPIC)‐Meso study (268 participants: 134 preclinical PM cases, 134 matched controls) within the EPIC cohort. Genome‐wide association analyses in the retrospective case–control study identified PM‐associated variants. The PRS (1123 SNPs with p < 0.001) in the retrospective training subset stratified disease risk in the test set (ORs 3.46–9.54 across top percentiles) and improved model discrimination (AUC = 0.75 vs. 0.71 in baseline model, p = 0.04). In EPIC‐Meso, PRS performance was limited (AUC = 0.52). External validation in the UK‐Biobank (UKBB) confirmed a modest but consistent association with PM‐risk. A Meta‐PRS derived from the UKBB‐FinnGen meta‐analysis replicated this trend in the full retrospective dataset, showing higher OR across top percentiles (2.5–12.3) and improved discrimination (AUC 0.74 vs. 0.72, p = 0.016). MRS, with 68 differentially methylated CpGs (effect‐size >|0.10|, FDR p < 0.05) in the retrospective training set, increased the AUC from 0.66 to 0.85 ( p < 0.001) in the test set and from 0.51 to 0.62 in EPIC‐Meso. PRS was most predictive in low‐exposure groups, while MRS remained robust across exposure levels. Combined PRS‐MRS models improved discrimination. Integrating multi‐omic biomarkers can enhance PM‐risk stratification and support earlier, targeted interventions in high‐risk asbestos‐exposed groups.